Abstract
Refractory eosinophilic duodenal bulb ulcers (REDU) following Helicobacter pylori (HP) eradication are rarely reported. This study aimed to investigate REDU in pediatric populations post-HP eradication. This multicenter retrospective analysis included children admitted to the Gastroenterology Departments of three children’s hospitals between January 1, 2016, and August 31, 2025. Eligible cases were pediatric patients diagnosed with REDU across the three centers. For the REDU group, clinical characteristics, laboratory tests, endoscopic findings, HP treatment strategies, and follow-up data were analyzed. Thirty patients (mean age 10.0 ± 3.4 years) were diagnosed with REDU, including 19 with HP eradication-related REDU and 11 with idiopathic REDU. Compared with HP-associated duodenal bulb ulcer (DBU) control group, the HP eradication-related REDU group had higher rates of anemia, elevated peripheral blood eosinophils (EOS) count, endoscopic giant DBU, bulbar stenosis, repeated endoscopies, and HP eradication therapies (all P < 0.01). REDU patients presented with punched-out DBU featuring a clean, thin white base; 76.7% (23/30) of REDU patients had giant DBU. Before treatment, among the entire REDU cohort, EOS counts 100 cells/HPF were noted in 17 cases (56.7%), while counts ≥ 50 cells/HPF were observed in 13 cases (43.3%). Serum cytokine assay showed that IL-8 was significantly elevated. All patients were treated with dietary avoidance and proton pump inhibitor (PPI) therapy. Recurrence was common, occurring in 9 of 16 patients (56.2%) following PPI dose reduction or discontinuation, with a median interval of 50.0 [35.0, 120.0] days. HP eradication may be associated with REDU in children via eosinophilic infiltration, emphasizing the need for systematic monitoring of immune-related complications post-eradication.
Data availability
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
References
Chey, W. D. et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 119 (9), 1730–1753 (2024).
Zhou, Y. et al. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter 25 (2), e12679 (2020).
Zhou, Y. et al. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter 25 (5), e12721 (2020).
Papadopoulou, A. et al. Joint ESPGHAN/NASPGHAN guidelines on childhood eosinophilic Gastrointestinal disorders beyond eosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 78 (1), 122–152 (2024).
Quinn, L. A. et al. Natural histories and disease complications in a cohort of 151 children with gastric or duodenal eosinophilia. Am. J. Gastroenterol. 119 (7), 1298–1308 (2024).
von Arnim, U. et al. Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis. Aliment. Pharmacol. Ther. 43 (7), 825–830 (2016).
Furuta, K. et al. Case-control study of association of eosinophilic Gastrointestinal disorders with Helicobacter pylori infection in Japan. J. Clin. Biochem. Nutr. 53 (1), 60–62 (2013).
Spinelli, I. et al. Meta-Analysis: inverse association between Helicobacter pylori infection and eosinophilic oesophagitis. Aliment. Pharmacol. Ther. 61 (7), 1096–1109 (2025).
Zhou, Y. et al. Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children. Helicobacter 26 (4), e12809 (2021).
Fujita, Y., Tominaga, K., Tanaka, T., Ishida, K. & Yoshihara, S. Eosinophilic duodenal ulcer exacerbation after Helicobacter pylori eradication in a 14-Year-Old Boy. Tohoku J. Exp. Med. 257 (2), 153–156 (2022).
Yeh, P. J. et al. The trends of pediatric duodenal ulcer and predictors of recurrence. J. Formos. Med. Assoc. 123 (10), 1070–1077 (2024).
Tang, Z. et al. The characteristics of 83 giant peptic ulcers in Chinese children: evaluation and follow-up. Saudi J. Gastroenterol. 24 (6), 360–364 (2018).
Fujita, Y., Tominaga, K., Ishida, K., Masuyama, H. & Yoshihara, S. Proton pump inhibitor to treat an eosinophilic duodenal ulcer with esophageal involvement: A pediatric case. Tohoku J. Exp. Med. 257 (4), 309–313 (2022).
Yamazaki, K. et al. A case of a teenage Boy with eosinophilic gastroenteritis with esophageal involvement developing a hemorrhagic duodenal ulcer. Clin. J. Gastroenterol. 8 (4), 179–185 (2015).
Licari, A. et al. Eosinophilic Gastrointestinal diseases in children: A practical review. Curr. Pediatr. Rev. 16 (2), 106–114 (2020).
Visaggi, P. & Dellon, E. S. Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases. Gastroenterology (2025).
Kobayashi, S. et al. Clinical features of pediatric eosinophilic gastroenteritis. Pediatr. Int. 64 (1), e15322 (2022).
Tsuge, M. et al. Successful use of dupilumab for egg-induced eosinophilic gastroenteritis with duodenal ulcer: a pediatric case report and review of literature. Allergy Asthma Clin. Immunol. 19 (1), 103 (2023).
Dellon, E. S. Eosinophilic Gastrointestinal diseases beyond eosinophilic esophagitis. Am. J. Gastroenterol. 117 (5), 697–700 (2022).
Migliorisi, G. et al. Eosinophils, eosinophilic Gastrointestinal Diseases, and inflammatory bowel disease: A critical review. J. Clin. Med. 13(14). (2024).
Rosenberg, H. F., Dyer, K. D. & Foster, P. S. Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol. 13 (1), 9–22 (2013).
Arias, A. et al. Toll-like receptors-mediated pathways activate inflammatory responses in the esophageal mucosa of adult eosinophilic esophagitis. Clin. Transl Gastroenterol. 9 (4), 147 (2018).
Homan, M. et al. Updated joint ESPGHAN/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023). J. Pediatr. Gastroenterol. Nutr. 79 (3), 758–785 (2024).
Shah, S. C. et al. Association between Helicobacter pylori exposure and decreased odds of eosinophilic Esophagitis-A systematic review and Meta-analysis. Clin. Gastroenterol. Hepatol. 17 (11), 2185–2198e2183 (2019).
Kobayashi, T. et al. Exploration of useful clinical laboratory values as diagnostic criteria for eosinophilic gastroenteritis. Eur. J. Gastroenterol. Hepatol. 36 (3), 292–297 (2024).
Doulberis, M., Kountouras, J. & Rogler, G. Reconsidering the protective hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Ann. N Y Acad. Sci. 1481 (1), 59–71 (2020).
Dellon, E. S. & Gupta, S. K. Pharmacologic management of Non-Eosinophilic esophagitis eosinophilic Gastrointestinal diseases. Immunol. Allergy Clin. North. Am. 44 (2), 397–406 (2024).
Chehade, M., Doerfler, B. & Atkins, D. Dietary management of Non-EoE eosinophilic Gastrointestinal diseases. Immunol. Allergy Clin. North. Am. 44 (2), 383–396 (2024).
Kubo, K. et al. Eosinophilic Gastroenteritis-associated duodenal ulcer successfully treated with crushed Budesonide. Intern. Med. 59 (18), 2249–2254 (2020).
Taniguchi, R. et al. Achievement of duodenal ulcer remission by Vedolizumab in children with eosinophilic gastroenteritis. Clin. J. Gastroenterol. 18 (2), 278–281 (2025).
Acknowledgements
We acknowledge the patients and their parents for their help for this study.
Funding
This research was supported by the grants from the National Key Research and Development Program of China 2023YFC2706501 and Shanghai Science and Technology Innovation Action Plan 23Y11905100.
Author information
Authors and Affiliations
Contributions
ZH and PL conceived the study and drafted the manuscript. YZ, XW, XZ, MJ, YM, SNW, CZ, LW, JL, ZT, and ZJ collected data. PS contributed to the statistical analyses. YH and YHW designed the study and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics statement
This study was approved by the Ethics Committee of the Children’s Hospital of Fudan University (Shanghai, China; IRB No.: 2024 (248)).
Consent
Written informed consent was obtained from all parents.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Huang, Z., Li, P., Zhou, Y. et al. Refractory eosinophilic duodenal bulb ulcer associated with Helicobacter pylori eradication in children: a multicenter study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-37351-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-37351-y
